Eight metabolism related genes including HMGCL, HMGCS1, CYP39A1, CYP2C9, CYP2E1, CYP2J2, CYP2S1, and CSGLCA-T have been screened to be potential synthetic lethal partners of BRAFV600E in melanomas, and HMGCL was finally validated as a synthetic lethal target of BRAFV600E.7 Similar to melanomas, there is a high prevalence of BRAFV600E mutation in thyroid cancers.14,15 Thus, we first analyzed the expression of these eight genes in PTCs from TCGA database. This evidence concerns the gene CYP2J2 and thyroid cancer.